Advent International has appointed healthcare veteran Dr. Lincoln Chee to its operating partner program in China, according to a company announcement.
Dr. Chee will advise and work with Advent to identify investment opportunities and develop portfolio companies in the Chinese healthcare sector.
He currently serves as a venture partner at Vertex Venture Holdings, a venture subsidiary of Temasek Holdings.
Advent International’s operating partner program includes over 60 senior industry executives, who help overhaul Advent’s portfolio companies.
Prior to joining Vertex, Dr. Chee was Chief Executive Officer and board member of Hong Kong-listed Quality Healthcare Asia from 2003 to 2012.
Over his eight year tenure, he led the restructuring and turnaround of the group, doubling revenues to HK$1.1 billion ($142m).
Previously, Dr. Chee led investments and held board positions at Arana Therapeutics in Sydney (acquired by Cephalon) and at Biosensors International, a leading drug eluting stent company listed on Singapore Stock Exchange.
Advent is a global private equity firm investing exclusively in mid to upper mid market buyouts and selective growth capital investments.